LIGAND PHARMACEUTICALS INC's ticker is and the CUSIP is 53220KAD0. A total of 23 filers reported holding LIGAND PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $61,701,000 | +28.1% | 17,500,000 | 0.0% | 0.34% | +15.3% |
| Q2 2018 | $48,149,000 | +25.8% | 17,500,000 | 0.0% | 0.29% | +18.1% |
| Q1 2018 | $38,265,000 | +67.0% | 17,500,000 | +40.0% | 0.25% | +112.8% |
| Q4 2017 | $22,910,000 | +0.5% | 12,500,000 | 0.0% | 0.12% | -33.5% |
| Q3 2017 | $22,799,000 | +9.7% | 12,500,000 | 0.0% | 0.18% | +14.3% |
| Q2 2017 | $20,783,000 | +10.9% | 12,500,000 | 0.0% | 0.15% | +4.8% |
| Q1 2017 | $18,732,000 | +85.2% | 12,500,000 | +78.6% | 0.15% | +83.8% |
| Q4 2016 | $10,116,000 | -1.4% | 7,000,000 | 0.0% | 0.08% | +9.6% |
| Q3 2016 | $10,263,000 | -13.4% | 7,000,000 | 0.0% | 0.07% | -12.0% |
| Q2 2016 | $11,855,000 | +10.9% | 7,000,000 | 0.0% | 0.08% | +16.9% |
| Q1 2016 | $10,692,000 | -1.8% | 7,000,000 | 0.0% | 0.07% | +2.9% |
| Q4 2015 | $10,893,000 | +20.0% | 7,000,000 | 0.0% | 0.07% | +9.5% |
| Q3 2015 | $9,074,000 | – | 7,000,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LINDEN ADVISORS LP | 57,915,000 | $89,697,000 | 5.40% |
| Man Investments (CH) AG | 4,000,000 | $6,224,000 | 2.47% |
| CAMDEN ASSET MANAGEMENT L P /CA | 38,150,000 | $58,846,000 | 1.85% |
| BASSO CAPITAL MANAGEMENT, L.P. | 7,720,000 | $11,947,000 | 1.77% |
| WOLVERINE ASSET MANAGEMENT LLC | 24,445,000 | $37,808,000 | 0.81% |
| CSS LLC/IL | 4,000,000 | $6,192,000 | 0.37% |
| PALISADE CAPITAL MANAGEMENT, LP | 4,800,000 | $7,440,000 | 0.24% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 3,922,000 | $6,193,000 | 0.10% |
| Calamos Advisors LLC | 7,000,000 | $10,893,000 | 0.07% |
| LAZARD ASSET MANAGEMENT LLC | 17,200,000 | $26,617,000 | 0.06% |